Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Drops By 52.8%

Achilles Therapeutics plc (NASDAQ:ACHL) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 57,800 shares, a drop of 52.8% from the January 15th total of 122,400 shares. Based on an average daily volume of 620,100 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are short sold.

Achilles Therapeutics Price Performance

NASDAQ ACHL opened at $1.38 on Thursday. Achilles Therapeutics has a 52-week low of $0.63 and a 52-week high of $1.76. The business’s 50-day moving average price is $1.14 and its 200 day moving average price is $0.99. The firm has a market cap of $56.72 million, a P/E ratio of -0.84 and a beta of 1.32.

Hedge Funds Weigh In On Achilles Therapeutics

A hedge fund recently raised its stake in Achilles Therapeutics stock. BML Capital Management LLC increased its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,100,002 shares of the company’s stock after buying an additional 3,474,828 shares during the quarter. Achilles Therapeutics comprises about 2.5% of BML Capital Management LLC’s holdings, making the stock its 11th largest position. BML Capital Management LLC owned approximately 9.98% of Achilles Therapeutics worth $4,182,000 as of its most recent filing with the Securities & Exchange Commission. 56.38% of the stock is currently owned by institutional investors and hedge funds.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.